Notice: Undefined variable: blnIsHomepage in /usr/local/apache/htdocs/igatecr/template/template_1.php on line 17
class="pgContentScroll" style="width: 589px;">
Fast Rescue Study Start-up
A new initiative of the India regulatory authority makes it possible to start your study in India within 6 weeks. This directive applies to any study that is currently approved and under way in the United States, the European Union, Japan, or another major country.
Access to Thousands of Patients
With a population exceeding 1 billion people and a well developed healthcare infrastructure, India has plenty of patients in virtually all therapeutic areas and indications.
In particular, India has a high prevalence of diabetes, cardiovascular disease, hepatitis, cancer, CNS indications, and infectious diseases. For most diseases the standard of care matches that in Western countries, including the same diagnostic tools and drugs. Still, because of lower health awareness, many "treatment-naïve" patients can also be found in all indications. Subpopulations that are rare in the United States, such as patients with unresectable tumors, may be accessed in India.
iGATE CR works with approximately 250 GCP investigators encompassing all the indications listed. For chronic diseases, these sites maintain active patient databases.
FDA-Quality Data
Since 1997, iGATE CR has managed more than 70 Phase I-IV clinical trials for international companies ranging from small biotech to large pharma. More than 50 of these clinical trials contributed Indian data to FDA submissions. In many of them iGATE CR provided the recruitment boost required to complete the study.
class="pgContentScroll" style="width: 589px;">
RAPID ASSIST Rescue Services
Thanks to India's unique regulatory and demographic environment, iGATE Clinical Research can help you get back on track.Fast Rescue Study Start-up
A new initiative of the India regulatory authority makes it possible to start your study in India within 6 weeks. This directive applies to any study that is currently approved and under way in the United States, the European Union, Japan, or another major country.
Access to Thousands of Patients
With a population exceeding 1 billion people and a well developed healthcare infrastructure, India has plenty of patients in virtually all therapeutic areas and indications.
In particular, India has a high prevalence of diabetes, cardiovascular disease, hepatitis, cancer, CNS indications, and infectious diseases. For most diseases the standard of care matches that in Western countries, including the same diagnostic tools and drugs. Still, because of lower health awareness, many "treatment-naïve" patients can also be found in all indications. Subpopulations that are rare in the United States, such as patients with unresectable tumors, may be accessed in India.
iGATE CR works with approximately 250 GCP investigators encompassing all the indications listed. For chronic diseases, these sites maintain active patient databases.
FDA-Quality Data
Since 1997, iGATE CR has managed more than 70 Phase I-IV clinical trials for international companies ranging from small biotech to large pharma. More than 50 of these clinical trials contributed Indian data to FDA submissions. In many of them iGATE CR provided the recruitment boost required to complete the study.
Need a Feasibility Study?
To find out more about our RAPID ASSIST program and how it may benefit your trial, please contact iGATE Clinical Research. In as little as two weeks, we will provide you a detailed analysis of the available patients and a realistic timeline for meeting your recruitment goal in India.
